Calliditas IPO To Support Phase III Berger's Disease Study

 
• By John Davis

Calliditas is aiming to raise new funding in an IPO and listing on Nasdaq Sweden to support late-stage clinical development and commercialization of its Berger's disease candidate, and studies in additional indications.  

Berger disease
IgA collects in the kidneys and causes inflammation. • Source: Shutterstock.

More from Financing

More from Business